2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5897 Nectin-4 as a novel ADC-targetable safety switch for adoptive cell therapy

Federico Mario Aletti, Jingwei Liu Sr2, Cao Cuong Cao Le, PhD, MSc3, Abdur Rehman4, Selin Kolsuz, MD5, Jinsheng Weng, MD, PhD6, Matthew D. Richard7, Xiaoyun Cheng, MD, MS8, Sridevi Patchva9, Yongfu Tang10, Chun-Yen Lin11, Karan L. Chohan, MD12, Fuliang Chu, PhD13, Jingjing Cao, BSc14, Swati Mohapatra, PhD15, Kamini Singh16, Shiv G. Rawat17, Jinsong Wei18, Faezeh Darbaniyan, PhD19, Neeraj Saini, MD20, Sattva S Neelapu Sr, MD21
1 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Background: The therapeutic success delivered in recent years by adoptive cellular therapy, including chimeric antigen receptor T (CAR T) cell therapy, has been accompanied by an inherent toxicity trade-off, linked to excessive cytokine release, on-target off-tumor toxicity, and the potential for product-derived neoplasms. Growing awareness of these risks has led to a demand for a means of post-infusion control of the cellular product. To this end several safety switches (SS) have been developed, including truncated surface proteins targeted by naked antibodies (RQR8/rituximab and tEGFR/cetuximab) or suicide genes activated by small molecules (HSV-TK/ganciclovir and iCas9/rimiducid). However, these SSs have had one or more limitations: variable efficacy, large transgene size, need for external effector cells, and/or lack of availability of a commercial agent to activate the SS. Here, we report a novel SS based on a truncated form of Nectin-4 (N4) targeted by enfortumab vedotin (EV), an FDA-approved antibody-drug conjugate (ADC), that addresses all the limitations of prior SSs.  

Methods and results: N4 is an epithelial adhesion molecule overexpressed in multiple solid tumors, yet it has minimal expression in healthy adult tissues and no detectable expression on immune cells. We engineered a truncated N4 (tN4) retaining only the extracellular domain containing the epitope recognized by EV and lacking the intracellular domain. A respective tN4-expression cassette was inserted downstream of an anti-CD19 CAR sequence in a bicistronic construct (19CAR.tN4). 19CAR.tN4-transduced primary T cells exhibited stable and consistent expression of the CAR and the SS over time. As the immune checkpoint receptor TIGIT has been reported to weakly interact with Nectin-4, we investigated whether tN4 could engage TIGIT in cis and/or in trans. No variation in TIGIT expression among untransduced (UTD) T cells, CD19 CAR T cells (19CAR), and 19CAR.tN4 was observed. This suggested absence of intracellular sequestration of either protein, and/or significant in cis interaction on the cell surface. Basal and stimulation-induced luciferase release did not differ significantly among Jurkat NFAT reporter cells transduced with 19CAR.tN4, co-transduced with 19CAR.tN4 and a TIGIT transgene, or transduced with 19CAR alone (all p>.05). We next assessed the cytotoxic efficacy of 19CAR.tN4 T cells in co-culture with target cells alone, or with target cells and TIGIT-expressing non-target cells. No statistically significant differences were observed between the two conditions (p=.25) or compared with 19CAR T cells (lacking the SS) under the same conditions (p=.10). This suggested that in trans interaction may not be functionally relevant. Following conjugation of enfortumab with a Fab-based pH-sensitive fluorescent antibody-labeling reagent, we proved that antibody internalization was 100% selective for tN4+ cells. No internalization was detected in 19CAR T cells or UTD T cells. Consistent with this, culturing 19CAR and 19CAR.tN4 T cells with EV demonstrated selective elimination of tN4+ cells. At one-tenth of the pharmacologic Cmax of EV more than 90% of CAR+ cells in the 19CAR.tN4 group were killed. In contrast, there was no decline in the 19CAR cell population. The efficacy of the SS was next validated in vivo. NSG mice received 1x107 19CAR.tN4 T cells followed by a single intravenous dose of IgG1k isotype control, polatuzumab-vedotin, or EV at 10 mg/kg. In the EV group, over 99% of CAR+ cells were eliminated in peripheral blood at days 4 and 7 post-treatment, or in spleen and bone marrow at necropsy (all p<.0001 vs. controls). 

Conclusions: Our novel ADC-based SS offers several advantages over current strategies. Compared with naked antibody-based SSs (RQR8 or tEGFR), EV (i) acts more rapidly and does not require additional immune effector cells to exert its cytotoxic effect; and (ii) unlike rituximab, which depletes normal B cells, EV is not expected to carry immunosuppressive potential. Compared with inducible apoptotic effectors (HSV-TK or iCas9), tN4 (i) can serve as a surface marker for tracking and sorting of transduced cells; (ii) is significantly shorter, facilitating incorporation into complex constructs; and (iii) leverages a commercially approved therapeutic agent. Together, our findings support the potential of this SS to provide a rapid, selective and clinically translatable solution for making engineered cell products safer. 

Federico Mario Aletti: No relevant conflicts of interest to declare.